HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) has begun working on a way to increase use of the anti-addiction drug Naltrexone as well as to expand access to treatment in Canada’s First Nations, Inuit and Métis indigenous populations, where addiction is becoming a serious health problem.
According to the Canadian Centre on Substance Abuse (CCSA), the nation’s indigenous communities are suffering a larger percentage of addiction to alcohol and opioids than the rest of the country. Surveys of the First Nations, Inuit and Métis have found people in those groups believe addiction and substance abuse to be the top challenge facing their communities (82.6 percent of all respondents) – greater even than housing (70.7 percent) and employment (65.9 percent).
Responding to the rising addiction rates, the Canadian government has instituted a National Framework for Action. The plan calls for Ottawa to work closely with indigenous groups such as the National Native Addictions Partnership Foundation (NNAPF) and Health Canada’s First Nations and Inuit Health Branch (FNIHB) to develop “meaningful, holistic and culturally appropriate solutions in the areas of access, prevention, health promotion, treatment and aftercare,” according to CCSA.
“RBCC is committed to working with the Canadian government, the CCSA and indigenous groups to halt this crisis,” said RBCC CEO Kimberly Palmer. “We embrace the First Do No Harm: Responding to Canada’s Prescription Drug Crisis strategy. It’s a great first step, but more needs to be done. So we’re working hard to ensure Canadian clinics have access to a durable, long-lasting Naltrexone protocol, such as the one being researched by RBCC. And we continue to explore low-cost addiction treatment options.”
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
